Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings Of The Fortnight Looks Ahead To The Annual Survey Of Life Sciences Venture Capital Firms

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financing activity by Novira Therapeutics, MediciNova, Elcelyx Therapeutics and Relypsa.

You may also be interested in...



Relypsa Adds Venture Funds In Another Effort To Reach Phase III

Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.

START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In

In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Related Companies

UsernamePublicRestriction

Register

PS074560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel